Patents Assigned to SYNESIS LLC
  • Publication number: 20210000851
    Abstract: Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are optionally bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.
    Type: Application
    Filed: September 14, 2020
    Publication date: January 7, 2021
    Applicants: UroPharma Limited, Synesis LLC
    Inventors: Howard Shapland, Scott Glickman, Christian G. Krueger, Army B. Howell, Jess D. Reed
  • Patent number: 10772901
    Abstract: Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 15, 2020
    Assignees: UroPharma Limited, Synesis LLC
    Inventors: Howard Shapland, Scott Glickman, Christian G. Krueger, Amy B. Howell, Jess D. Reed
  • Publication number: 20180000853
    Abstract: Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 4, 2018
    Applicants: UROPHARMA LIMITED, SYNESIS LLC
    Inventors: Howard SHAPLAND, Scott Glickman, Christian G. Krueger, Amy B. Howell, Jess D. Reed